Összesen 1 találat.


001-es BibID:BIBFORM097681
035-os BibID:(cikkazonosító)725465 (WOS)000717701800001 (Scopus)85118968206
Első szerző:Rokszin György
Cím:Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors : data of the Post-Hoc Analysis of a Nationwide Study / Rokszin György, Kiss Zoltán, Sütő Gábor, Kempler Péter, Jermendy György, Fábián Ibolya, Szekanecz Zoltán, Poór Gyula, Wittmann István, Molnár Gergő Attila
Megjegyzések:Background: In diabetes mellitus, during the last years, cancer became of equivalent importance as a cardiovascular disease in terms of mortality. In an earlier study, we have analyzed data of the National Health Insurance Fund (NHIF) of Hungary with regards all patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors (SGLT2is) vs. those treated with dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4is) in a given timeframe. In propensity score-matched groups of SGLT2i- vs. DPP-4i-treated patients, we found a lower incidence of cancer in general. In this post-hoc analysis, we aimed to obtain data on the incidence of site-specific cancer. Patients and Methods: All patients starting an SGLT2i or a DPP-4i between 2014 and 2017 in Hungary were included; the two groups (SGLT2i vs. DPP-4i) were matched for 54 clinical and demographical parameters. The follow-up period was 639 vs. 696 days, respectively. Patients with a letter "C" International Classification of Diseases, 10th Revision (ICD-10) code have been chosen, and those with a known malignancy within a year before the onset of the study have been excluded from the analysis. Results: We found a lower risk of urinary tract [HR 0.50 (95% CI: 0.32?0.79) p = 0.0027] and hematological malignancies [HR 0.50 (95% CI: 0.28?0.88) p = 0.0174] in patients treated with SGLT2i vs. those on DPP-4i. Risk of other types of cancer (including lung and Frontiers in Oncology | www.frontiersin.org 1 October 2021 | Volume 11 | Article 725465 Edited by: Vincenzo Quagliariello, Istituto Nazionale Tumori Fondazione G. Pascale (IRCCS), Italy Reviewed by: Keizo Kanasaki, Shimane University, Japan Yoshifumi Saisho, Keio University, Japan *Correspondence: Istva? n Wittmann wittmann.istvan@pte.hu Specialty section: This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology Received: 29 June 2021 Accepted: 30 September 2021 Published: 28 October 2021 Citation: Rokszin G, Kiss Z, Süto? G, Kempler P, Jermendy G, Fa? bia? n I, Szekanecz Z, Poo? r G, Wittmann I and Molna?r GA (2021) Sodium-Glucose CoTransporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study. Front. Oncol. 11:725465. doi: 10.3389/fonc.2021.725465 ORIGINAL RESEARCH published: 28 October 2021 doi: 10.3389/fonc.2021.725465 larynx, lower gastrointestinal (GI) tract, rectum, pancreas, non-melanoma skin cancers, breast, or prostate) did not differ significantly between the two groups. When plotting absolute risk difference against follow-up time, an early divergence of curves was found in case of prostate, urinary tract, and hematological malignancies, whereas late divergence can be seen in case of cancers of the lung and larynx, the lower GI tract, and the breast. Conclusions: Urinary tract and hematological malignancies were less frequent in patients treated with SGLT2i vs. DPP-4i. An early vs. late divergence could be observed for different cancer types, which deserves further studies.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
diabetes mellitus type 2
antidiabetic treatment
dipeptidyl peptidase (DPP)-4 inhibitors
sodiumglucose co-transporter 2 (SGLT 2) inhibitors
Megjelenés:Frontiers in Oncology. - 11 (2021), p. 1-9. -
További szerzők:Kiss Zoltán (Budapest) Sütő Gábor Kempler Péter (1954-) (belgyógyász, diabetológus) Jermendy György Fábián Ibolya Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Poór Gyula Wittmann István Molnár Gergő Attila
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Rekordok letöltése1